MGX (metagenomi.co) Net Profit

MGX (Metagenomi) - company brandmark

Metagenomi, Inc. (MGX) aims for global leadership in precision genome editing through B2B alliances. The company's profit history on the GURU.Markets chart shows that -0.09 is the current value of the indicator. High research and development costs are hindering operational growth. Meanwhile, the lack of commercial products makes finances dependent on external funding and partner payments.

MGX Metagenomi: Net Profit in the range 02/21/2024 - 11/01/2026

Analytical breakdowns and data insights for company Metagenomi (MGX)

- share price and expert price forecast:
Price Metagenomi Therapeutics|MGX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Metagenomi Therapeutics|MGX - Enterprise Value
- book capitalization data:
Book Value of One Share Metagenomi|MGX - Book Capitalization|Market-to-Book Ratio metagenomi.co|MGX - Aggregate Company Assets
- debt burden and liquidity indicators:
Debt to Equity Ratio Metagenomi, Inc.|MGX - Long-Term Debt to Equity|Current Liabilities to Capital Metagenomi Inc.|MGX - Company Debts|Debt to Book Value Metagenomi Therapeutics|MGX - Company Long-Term Debts|Short-Term Debt Volume Metagenomi|Intermediate Coverage Ratio metagenomi.co
- business earnings and investment ratios data:
MGX - Net Profit
Basic company analysis:MGX, Metagenomi Therapeutics
Brand item of Metagenomi, Inc.

To minimize long-term capital risks, it is necessary to correlate historical earnings volatility with current Fed monetary policy. An analysis of Metagenomi, Inc. (MGX) annual financial results allows for an assessment of investment efficiency in elite CRISPR developments and metagenomic libraries, where net income reflects the business's ability to convert scientific potential and support from pharma behemoths into actual cash flow, thereby determining the final investment profile of Metagenomi, Inc. (MGX).

Direct competitors

TEM: Profit After Payment of Taxes|QGEN (Qiagen N.V.) - Net Profit|Net Profit ionispharma.com|Net Profit RGEN|Avidity Biosciences Inc (RNA) - Annual Net Income|Net Profit CRSP (CRISPR Therapeutics Corp)|GeneDx Corp (WGS) - Company Net Income|RARE - Company Net Income|BEAM (beamtx.com) - Company Profit|Sarepta (SRPT) - Company Net Income|Company Net Income Twist Bioscience Inc (TWST)|Company Net Income 10x Genomics Corp|Net Income Intellia Corp (NTLA)|Net Profit STOK|Net Financial Result biolifesolutions.com|Wave Life Sciences Ltd. - Net Income|Final Profit MAZE|Sionna Pharma - Net Profit|Net Financial Result Prime Medicine Bio PRME|Taysha Gene Therapies (TSHA) - Company Net Income|Company Profit QURE|MGTX (MeiraGTx) - Net Profit|Net Income REGENXBIO Inc (RGNX)|Net Income SLDB (Solid Bio)|Net Financial Result Ocugen Pharma|Company Net Income Pacific Biosciences PACB|BNTC - Net Income|Design Therapeutics, Inc. - Net Profit|Annual Net Income Rocket Pharma (RCKT)|FDMT (4D Molecular Therapeutics Inc) - Net Income|Company Profit LXEO|KRRO (Korro Bio Inc.) - Net Profit|Company Profit EDIT (editasmedicine.com)|Company Net Income Silence Therapeutics plc (SLN)|proqr.com - Company Profit|Net Profit CDXS (Codexis)|Net Profit Sangamo BioSciences SGMO|NAUT - Company Net Income|Precision BioSciences Inc. (DTIL) - Net Income|GBIO: Net Profit|Company Net Income Boundless Bio Inc. (BOLD)|Net Income XCUR|IMNN (Celsion Corporation) - Profit After Payment of Taxes|Net Profit PHIO|Net Profit mustangbio.com (MBIO)|Net Profit RNAZ (TransCode Therapeutics, Inc.)|Annual Net Income Bionano Genomics Inc.|Applied DNA - Net Profit|Company Net Income bluebird bio, Inc|immunoprecise.com (IPA) - Company Net Income|Company Profit OMGA|Company Net Income Singular Genomics|Company Net Income Regulus Therapeutics, Inc. RGLS|Company Net Income Syros (SYRS)|Net Income Telesis Bio, Inc TBIO|Net Profit TCON (TRACON Pharmaceuticals)|Net Financial Result unitybiotechnology.com (UBX)